Immunization with Toxoplasma Gondii Peroxiredoxin 1 Induces Protective Immunity Against Toxoplasmosis in Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Apr 28

PMID 28448521

Citations 14

Authors

Ragab M Fereig

Yasuhiro Kuroda

Mohamad Alaa Terkawi

Motamed Elsayed Mahmoud

Yoshifumi Nishikawa

Affiliations

Soon will be listed here.

Abstract

To develop a vaccine against Toxoplasma gondii, a vaccine antigen with immune-stimulating activity is required. In the present study, we investigated the immunogenicity and prophylactic potential of T. gondii peroxiredoxin 1 (TgPrx1). The TgPrx1 was detected in the ascitic fluid of mice 6 days postinfection, while specific antibody levels were low in the sera of chronically infected mice. Treatment of murine peritoneal macrophages with recombinant TgPrx1 triggered IL-12p40 and IL-6 production, but not IL-10 production. In response to TgPrx1, activation of NF-kB and IL-6 production were confirmed in mouse macrophage cell line (RAW 264.7). These results suggest the immune-stimulating potentials of TgPrx1. Immunization of mice with recombinant TgPrx1 stimulated specific antibody production (IgG1 and IgG2c). Moreover, spleen cell proliferation and interferon-gamma production significantly increased in the TgPrx1- sensitized cells from mice immunized with the same antigen. Immunization with TgPrx1 also increased mouse survival and decreased cerebral parasite burden against lethal T. gondii infection. Thus, our results suggest that TgPrx1 efficiently induces humoral and cellular immune responses and is useful as a new vaccine antigen against toxoplasmosis.

Citing Articles

Evaluation of Immunodiagnostic Performances of Peroxiredoxin 2 (NcPrx2), Microneme 4 (NcMIC4), and Surface Antigen 1 (NcSAG1) Recombinant Proteins for Bovine Neosporosis.

Udonsom R, Adisakwattana P, Popruk S, Reamtong O, Jirapattharasate C, Thiangtrongjit T Animals (Basel). 2024; 14(4).

PMID: 38396498 PMC: 10885977. DOI: 10.3390/ani14040531.

Recent progress in vaccine development targeting pre-clinical human toxoplasmosis.

Chu K, Quan F Parasites Hosts Dis. 2023; 61(3):231-239.

PMID: 37648228 PMC: 10471472. DOI: 10.3347/PHD.22097.

Prx4 acts as DAMP in shrimp, enhancing bacterial resistance via the toll pathway and prophenoloxidase activation.

Wanvimonsuk S, Jaree P, Kawai T, Somboonwiwat K iScience. 2023; 26(1):105793.

PMID: 36619979 PMC: 9813724. DOI: 10.1016/j.isci.2022.105793.

Immunoproteomics to identify species-specific antigens in Neospora caninum recognised by infected bovine sera.

Udonsom R, Reamtong O, Adisakwattana P, Popruk S, Jirapattharasate C, Nishikawa Y Parasite. 2022; 29:60.

PMID: 36562441 PMC: 9879140. DOI: 10.1051/parasite/2022059.

Exploiting the Macrophage Production of IL-12 in Improvement of Vaccine Development against and Infections.

Fereig R, Omar M, Alsayeqh A Vaccines (Basel). 2022; 10(12).

PMID: 36560492 PMC: 9783364. DOI: 10.3390/vaccines10122082.

References

Akerman S, Muller S . Peroxiredoxin-linked detoxification of hydroperoxides in Toxoplasma gondii. J Biol Chem. 2004; 280(1):564-70. DOI: 10.1074/jbc.M406367200. View

Gazzinelli R, Hieny S, Wynn T, Wolf S, Sher A . Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A. 1993; 90(13):6115-9. PMC: 46878. DOI: 10.1073/pnas.90.13.6115. View

Innes E, Bartley P, Maley S, Katzer F, Buxton D . Veterinary vaccines against Toxoplasma gondii. Mem Inst Oswaldo Cruz. 2009; 104(2):246-51. DOI: 10.1590/s0074-02762009000200018. View

Chae H, Robison K, Poole L, Church G, Storz G, Rhee S . Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci U S A. 1994; 91(15):7017-21. PMC: 44329. DOI: 10.1073/pnas.91.15.7017. View

Morgado P, Sudarshana D, Gov L, Harker K, Lam T, Casali P . Type II Toxoplasma gondii induction of CD40 on infected macrophages enhances interleukin-12 responses. Infect Immun. 2014; 82(10):4047-55. PMC: 4187859. DOI: 10.1128/IAI.01615-14. View

Rodriguez J, Szajnman S . New antibacterials for the treatment of toxoplasmosis; a patent review. Expert Opin Ther Pat. 2012; 22(3):311-33. DOI: 10.1517/13543776.2012.668886. View

Fereig R, Nishikawa Y . Peroxiredoxin 3 promotes IL-12 production from macrophages and partially protects mice against infection with Toxoplasma gondii. Parasitol Int. 2016; 65(6 Pt A):741-748. DOI: 10.1016/j.parint.2016.09.008. View

Hassan I, Wang S, Xu L, Yan R, Song X, Li X . Immunoglobulin and cytokine changes induced following immunization with a DNA vaccine encoding Toxoplasma gondii selenium-dependent glutathione reductase protein. Exp Parasitol. 2014; 146:1-10. DOI: 10.1016/j.exppara.2014.08.011. View

Mahmoud M, Ui F, Salman D, Nishimura M, Nishikawa Y . Mechanisms of interferon-beta-induced inhibition of Toxoplasma gondii growth in murine macrophages and embryonic fibroblasts: role of immunity-related GTPase M1. Cell Microbiol. 2015; 17(7):1069-83. DOI: 10.1111/cmi.12423. View

10.

Buxton D . Toxoplasmosis: the first commercial vaccine. Parasitol Today. 1993; 9(9):335-7. DOI: 10.1016/0169-4758(93)90236-9. View

11.

Wang H, Li Y, Yin L, Meng X, Guo M, Zhang J . Toxoplasma gondii protein disulfide isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosis. PLoS One. 2013; 8(8):e70884. PMC: 3744524. DOI: 10.1371/journal.pone.0070884. View

12.

Mendes R, Perez-Ecija R, Zafra R, Buffoni L, Martinez-Moreno A, Dalton J . Evaluation of hepatic changes and local and systemic immune responses in goats immunized with recombinant Peroxiredoxin (Prx) and challenged with Fasciola hepatica. Vaccine. 2010; 28(16):2832-40. DOI: 10.1016/j.vaccine.2010.01.055. View

13.

Dziadek B, Gatkowska J, Brzostek A, Dziadek J, Dzitko K, Dlugonska H . Toxoplasma gondii: the immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosis. Exp Parasitol. 2009; 123(1):81-9. DOI: 10.1016/j.exppara.2009.06.002. View

14.

McGonigle S, Dalton J, James E . Peroxidoxins: a new antioxidant family. Parasitol Today. 2006; 14(4):139-45. DOI: 10.1016/s0169-4758(97)01211-8. View

15.

Robert-Gangneux F, Darde M . Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012; 25(2):264-96. PMC: 3346298. DOI: 10.1128/CMR.05013-11. View

16.

Deponte M, Becker K . Biochemical characterization of Toxoplasma gondii 1-Cys peroxiredoxin 2 with mechanistic similarities to typical 2-Cys Prx. Mol Biochem Parasitol. 2005; 140(1):87-96. DOI: 10.1016/j.molbiopara.2004.12.008. View

17.

Butcher B, Kim L, Johnson P, Denkers E . Toxoplasma gondii tachyzoites inhibit proinflammatory cytokine induction in infected macrophages by preventing nuclear translocation of the transcription factor NF-kappa B. J Immunol. 2001; 167(4):2193-201. DOI: 10.4049/jimmunol.167.4.2193. View

18.

Furuta T, Imajo-Ohmi S, Fukuda H, Kano S, Miyake K, Watanabe N . Mast cell-mediated immune responses through IgE antibody and Toll-like receptor 4 by malarial peroxiredoxin. Eur J Immunol. 2008; 38(5):1341-50. DOI: 10.1002/eji.200738059. View

19.

Tato C, Villarino A, Caamano J, Boothby M, Hunter C . Inhibition of NF-kappa B activity in T and NK cells results in defective effector cell expansion and production of IFN-gamma required for resistance to Toxoplasma gondii. J Immunol. 2003; 170(6):3139-46. DOI: 10.4049/jimmunol.170.6.3139. View

20.

Almeida F, Sardinha-Silva A, da Silva T, Pessoni A, Pinzan C, Alegre-Maller A . Toxoplasma gondii Chitinase Induces Macrophage Activation. PLoS One. 2015; 10(12):e0144507. PMC: 4684212. DOI: 10.1371/journal.pone.0144507. View